Ares Genetics GmbH

Ares Genetics is a healthcare-IT driven molecular diagnostic start-up working towards revolutionizing infectious disease diagnostics and therapeutics by artificial intelligence based DNA testing to improve patient outcomes at reduced costs.

Microbial Infections and antimicrobial resistance (AMR) have become a major healthcare challenge causing more than 15 million casualties annually. The rapidly spreading AMR problem is largely fueled by the indiscriminate use of broadband antibiotics. This is mostly due to the absence of diagnostic information on the causative pathogens and associated resistance patterns at the time of prescription, as current diagnostic methods usually take 48 to 72 hours to deliver actionable information.

To address this challenge with a disruptive, data-driven approach, Ares Genetics, currently headquartered in Vienna, Austria, was founded in 2017 as a subsidiary of the molecular diagnostics company Curetis GmbH by an experienced team of diagnostics industry, bioinformatics, and data science professionals.

Ares Genetics builds on its proprietary pathogen and AMR reference database, ARESdb, the world’s most comprehensive database on the genetics of AMR and which was originally established by the Ares Genetics Management Team at Siemens and acquired by Ares Genetics. Ares Genetics’ vision is to revolutionize infectious disease diagnostics by translating success stories from molecular diagnostics in cancer to microbial infections. To achieve this, Ares Genetics makes use of high-resolution Next Generation Sequencing (NGS) technology in combination with ARESdb and artificial intelligence for result interpretation as well as an extensive IP portfolio covering AMR biomarkers, sample preparation technologies, bioinformatics methods and algorithms.

Currently, the ARES solutions portfolio comprises of diagnostics and pharma services. The company offers research use only testing services, and is working on the development of diagnostic testing services from native patient samples to be eventually offered as IVD test kit for use by any laboratory worldwide. To accelerate discovery and development of novel antibiotics, Ares Genetics offers a comprehensive portfolio of data-driven services for antimicrobial drug discovery, clinical development, and product lifecycle management. Ares Genetics pharma services support data-driven target and lead prioritization, accelerate clinical trials, augment clinical data for regulatory submissions, as well as inform antimicrobial use for effective antibiotic stewardship post launch.

Schlagworte

Website

http://www.ares-genetics.com